Document:

Exhibit 10.38

AMENDMENT

This AMENDMENT #2 (this “Amendment 2”), dated as of March 31, 2006,
but  effective as of August 25, 2005 (“Amendment
Effective Date”), is entered into by and between IWT TESORO CORPORATION, a
Nevada corporation (the “Company”),
INTERNATIONAL WHOLESALE TILE INC., a Florida corporation (“Tile” and, together with the Company, the “Credit Parties” and, each a “Credit Party”) and LAURUS MASTER FUND, LTD., a Cayman Islands company (“Laurus”), for the purpose of amending the
terms of (i) the Security Agreement, dated as of August 25, 2005, by and
between the Credit Parties and Laurus (as amended, modified or supplemented
from time to time, the “Security Agreement”)
and (ii) the Convertible Minimum Borrowing Note by and between the Company and
Credit Parties, dated as of August 25, 2005 (as amended, modified or
supplemented from time to time, the ”Minimum Note” and, together with the
Security Agreement and the other Ancillary Documents referred to in the
Security Agreement, the ”Loan Documents”).
Capitalized terms used herein without definition shall have the meanings
ascribed to such terms in the Security Agreement.

A.            The Credit Parties and Laurus agree to amend the Minimum
Note in order to accurately reflect the intent of the parties.

NOW, THEREFORE, in
consideration of the above, and for other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties hereto
agree as follows:

1.             Sections 3.6 (c) Share Issuances and 3.6(d) Computation
of Consideration of the Minimum Note shall be deleted in their entirety and
shall have no further forth or effect.

2.             The Company understands that the Company has an
affirmative obligation to make prompt public disclosure of material agreements
and material amendments to such agreements. The Company hereby agrees that
Laurus shall not be in violation of any duty to the Company or its
shareholders, nor shall Laurus be deemed to be misappropriating any information
of the Company, if Laurus sells shares of common stock of the Company, or
otherwise engages in transactions with respect to securities of the Company,
while in possession of the information contained in this Amendment.

3.             Each Credit Party hereby represents and warrants to
Laurus that (i) no Event of Default exists on the date hereof, (ii) on the date
hereof, all representations, warranties and covenants made by the Company in
connection with the Loan Documents are true, correct and complete and (iii) on
the date hereof, all of the Company’s and its Subsidiaries’ covenant
requirements have been met.

4.             From and after the Amendment Effective Date, all
references in the Loan Documents and in the other Related Agreements to the
Minimum Note shall be deemed to reference to the Minimum Note, as the case may
be, as modified hereby.

5.             This Amendment shall be binding upon the parties hereto
and their respective successors and permitted assigns and shall inure to the
benefit of and be enforceable by each of the parties hereto and their
respective successors and permitted assigns. THIS
AMENDMENT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH AND GOVERNED BY
THE LAW OF THE STATE OF NEW YORK. This Amendment may be
executed in any number of counterparts, each of which shall be an original, but
all of which shall constitute one instrument.

 

 

IN WITNESS WHEREOF, each Credit Party and
Laurus have caused this Amendment to the Loan Documents to be signed in its
name as of this      day of           ,
2006, but shall be effective as of the Amendment Effective Date...

 

	
  

  	
   

  	
  IWT TESORO CORPORATION

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  Henry J. Boucher, Jr., President and CEO

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  INTERNATIONAL WHOLESALE TILE, INC.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  Paul F. Boucher, President

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  LAURUS MASTER FUND, LTD.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
  Name:

  	
   

  
	
   

  	
  Title:Exhibit 10.24

PONIARD PHARMACEUTICALS,
INC.

KEY EXECUTIVE SEVERANCE AGREEMENT (VP)

This Key Executive Severance Agreement (VP) (this “Agreement”), dated as of July 24,
2006, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington
corporation (as supplemented by Section 10, the “Company”),
and Alan B. Glassberg, M.D. (the “Executive”).

The Board of Directors of the Company (the “Board”) has determined that it is in
the best interests of the Company and its shareholders to ensure that the
Company will have the continued dedication of the Executive, notwithstanding
the fact that the Executive does not have any form of traditional employment
contract or other assurance of job security. The Board believes it is
imperative to diminish any distraction of the Executive arising from the
personal uncertainty and insecurity that arises in the absence of any assurance
of job security by providing the Executive with reasonable compensation and
benefit arrangements in the event of termination of the Executive’s employment
by the Company under certain defined circumstances.

In order to accomplish
these objectives, the Board has caused the Company to enter into this
Agreement.

1.                 Term

The initial term of this
Agreement (the “Initial Term”) shall be for a
period of one (1) year from the date of this Agreement as first appearing;
provided, however, that this Agreement shall automatically renew for successive
additional one (1) year periods (“Renewal Terms”),
unless notice of nonrenewal is given by either party to the other party at
least nine (9) months prior to the end of the Initial Term or any Renewal
Term, and provided further that if a Change of Control (as defined in the
Change of Control Agreement referenced in Section 16 hereof) occurs during
the Term, the Term shall automatically extend for the duration of the
Employment Period (as defined in the Change of Control Agreement). The “Term” of this Agreement shall be the
Initial Term plus all Renewal Terms and, if applicable, the duration of the
Employment Period. At the end of the Term, this Agreement shall terminate
without further action by either the Company or the Executive.

2.                 Employment

The Executive and the
Company acknowledge that, except as may otherwise be provided under any other written
agreement between the Executive and the Company, the employment of the
Executive by the Company or by any affiliated or successor company is “at will”
and may be terminated by either the Executive or the Company or its affiliated
companies at any time with or without cause, subject to the termination
payments prescribed herein.

3.                 Attention
and Effort

During any period of time
that the Executive remains in the employ of the Company, and excluding any
periods of vacation and sick leave to which the Executive is entitled, the
Executive will devote all his productive time, ability, attention and effort to
the business and affairs of the Company and the discharge of the
responsibilities assigned to him hereunder, and will seek to perform faithfully
and efficiently such responsibilities. It shall not be a violation of this
Agreement for the Executive to (a) serve on corporate, civic or charitable
boards or committees, (b) deliver lectures, fulfill speaking engagements
or teach at educational institutions, (c) manage personal investments, or (d) engage
in activities permitted by the policies of the Company or as specifically
permitted by the Company, so long as such activities do not significantly
interfere with the performance of the Executive’s responsibilities in
accordance with this Agreement. It is expressly understood and agreed that to
the extent any such activities have been conducted by the Executive prior to
the Term, the continued conduct of such activities (or the conduct of 

activities
similar in nature and scope thereto) during the Term shall not thereafter be
deemed to interfere with the performance of the Executive’s responsibilities to
the Company.

4.                 Termination

During the Term,
employment of the Executive may be terminated as follows, but, in any case, the
nondisclosure provisions set forth in Section 7 hereof shall survive the
termination of this Agreement and the termination of the Executive’s employment
with the Company:

4.1   By the
Company or the Executive

At any time during the Term, the Company may terminate
the employment of the Executive with or without Cause (as defined below), and
the Executive may terminate his employment for Good Reason (as defined below)
or for any reason, upon giving Notice of Termination (as defined below).

4.2   Automatic
Termination

This Agreement and the
Executive’s employment shall terminate automatically upon the death or Total
Disability of the Executive. The term “Total Disability”
as used herein shall mean the Executive’s inability (with such accommodation as
may be required by law and which places no undue burden on the Company), as
determined by a physician selected by the Company and acceptable to the
Executive, to perform the Executive’s essential duties for a period or periods
aggregating twelve (12) weeks in any three hundred sixty-five (365) day period
as a result of physical or mental illness, loss of legal capacity or any other
cause beyond the Executive’s control, unless the Executive is granted a leave
of absence by the Board.

4.3   Notice of
Termination

Any termination by the
Company or by the Executive during the Term shall be communicated by Notice of
Termination to the other party given in accordance with Section 9 hereof. The
term “Notice of Termination” shall
mean a written notice that (a) indicates the specific termination
provision in this Agreement relied upon and (b) to the extent applicable,
sets forth in reasonable detail the facts and circumstances claimed to provide
a basis for termination of the Executive’s employment under the provision so
indicated. The failure by the Executive or the Company to set forth in the
Notice of Termination any fact or circumstance that contributes to a showing of
Good Reason or Cause shall not waive any right of the Executive or the Company
hereunder or preclude the Executive or the Company from asserting such fact or
circumstance in enforcing the Executive’s or the Company’s rights hereunder.

4.4   Date of
Termination

“Date
of Termination” means (a) if the Executive’s employment is
terminated by reason of death, the last day of the calendar month in which the
Executive’s death occurs, (b) if the Executive’s employment is terminated
by reason of Total Disability, immediately upon a determination by the
Company of the Executive’s Total Disability, and (c) in all other cases,
ten (10) days after the date of personal delivery or mailing of the Notice
of Termination. The Executive’s employment and performance of services will
continue during such ten (10) day period; provided, however, that the
Company may, upon notice to the Executive and without reducing the Executive’s
compensation during such period, excuse the Executive from any or all of his
duties during such period.

5.                 Termination
Payments

In the event of
termination of the Executive’s employment during the Term, all compensation and
benefits shall terminate, except as specifically provided in this Section 5.

 2
 

5.1   Termination
by the Company Other Than for Cause or by the Executive for Good Reason

If during the Term
the Company terminates the Executive’s employment other than for Cause or the
Executive terminates his employment for Good Reason, the Executive shall be
entitled to:

(a)   receive
payment of the following accrued obligations (the “Accrued
Obligations”):

(i)    the
Executive’s then current annual base salary through the Date of Termination to
the extent not theretofore paid; and

(ii)   any
compensation previously deferred by the Executive (together with accrued
interest or earnings thereon, if any) and any accrued vacation pay that would
be payable under the Company’s standard policy, in each case to the extent not
theretofore paid;

(b)   for nine (9) months
after the Date of Termination or until the Executive qualifies for comparable
medical and dental insurance benefits from another employer, whichever occurs
first, the Company shall pay the Executive’s premiums for health insurance
benefit continuation for the Executive and his family members, if applicable,
that the Company provides to the Executive under the provisions of the federal
Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), to the extent that the
Company would have paid such premiums had the Executive remained employed by
the Company (such continued payment is hereinafter referred to as “COBRA Continuation”); and

(c)   an amount as severance pay equal to seventy five percent (75%) of
the Executive’s then current annual base salary for the fiscal year in which
the Date of Termination occurs, subject to payment as set forth in
Sections 5.5 and 5.9 hereof.

5.2   Termination
for Cause or Other Than for Good Reason

If during the Term the
Executive’s employment shall be terminated by the Company for Cause or by the
Executive for other than Good Reason, this Agreement shall terminate without
further obligation on the part of the Company to the Executive, other than the
Company’s obligation to pay the Executive the Accrued Obligations to the extent
theretofore unpaid.

5.3   Expiration
of Term

In the event the Executive’s
employment is not terminated prior to expiration of the Term, this Agreement
shall terminate without further obligation on the part of the Company to the
Executive.

5.4   Termination
Because of Death or Total Disability

If the Executive’s
employment is terminated during the Term by reason of the Executive’s death or
Total Disability, this Agreement shall terminate automatically without further
obligation on the part of the Company to the Executive or his legal representatives
under this Agreement, other than the Company’s obligation to pay the Executive
the Accrued Obligations (which shall be paid to the Executive’s estate or
beneficiary, as applicable in the case of the Executive’s death) and to provide
COBRA Continuation.

5.5   Payment
Schedule

All payments of Accrued
Obligations, or any portion thereof payable pursuant to this Section 5,
shall be made to the Executive within ten (10) working days of the Date of
Termination. Any severance payments payable to the Executive pursuant to Section 5.1(c) shall
be made to the Executive in the form of salary continuation, payable at normal
payroll intervals during the nine (9) month period following the Date of
Termination (“Payment Period”).

 3
 

5.6   Cause

For purposes of
this Agreement, “Cause” means cause given by
the Executive to the Company and shall include, without limitation, the
occurrence of one or more of the following events:

(a)   a clear
refusal to carry out any material lawful duties of the Executive or any
directions of the Board or senior management of the Company reasonably
consistent with those duties;

(b)   persistent
failure to carry out any lawful duties of the Executive or any directions of
the Board or senior management reasonably consistent with those duties; provided,
however, that the Executive has been given reasonable notice and opportunity to
correct any such failure;

(c)   violation
by the Executive of a state or federal criminal law involving the commission of
a crime against the Company or any other criminal act involving moral
turpitude;

(d)   current
abuse by the Executive of alcohol or controlled substances; deception, fraud,
misrepresentation or dishonesty by the Executive; or any incident materially
compromising the Executive’s reputation or ability to represent the Company
with investors, customers or the public; or

(e)   any other material violation of any provision of this Agreement by
the Executive, subject to the notice and opportunity to cure requirements of Section 8
hereof.

5.7   Good
Reason

For purposes of
this Agreement, “Good Reason” means:

(a)   reduction
of the Executive’s annual base salary to a level below the level in effect on
the date of this Agreement, regardless of any change in the Executive’s duties
or responsibilities;

(b)   the
assignment to the Executive of any duties materially inconsistent with the
Executive’s position, authority, duties or responsibilities or any other action
by the Company the results in a material diminution in such position,
authority, duties or responsibilities, excluding for this purpose an isolated
and inadvertent action not taken in bad faith and that is remedied by the
Company promptly after receipt of notice thereof given by the Executive;

(c)   the Company’s
requiring the Executive to be based at any office or location more than fifty (50) miles
from the city in which the Executive will be employed by the Company, i.e., San
Francisco, California or Seattle, Washington;

(d)   any failure
by the Company to comply with and satisfy Section 10 hereof, provided,
however, that the Company’s successor has received at least ten (10) days’
prior written notice from the Company or the Executive of the requirements of Section 10
hereof; or

(e)   any other material violation of any provision of this Agreement by
the Company, subject to the notice and opportunity to cure requirements of Section 8
hereof.

5.8   General
Release of Claims

As a condition to the
payment contemplated by Section 5.1(c), the Executive shall execute a
general release of claims against the Company in a form satisfactory to the
Company in its sole discretion. By way of example and not limitation, the
general release of claims will include any claims for wages, bonuses,
employment benefits, or damages of any kind whatsoever, arising out of any
contracts, express or implied, any covenant of good faith and fair dealing,
express or implied, any theory of wrongful discharge, any legal restriction on
the Company’s right to terminate employment, or any federal, state or other
governmental statute or ordinance, including, without limitation, Title VII of
the Civil Rights Act of 1964, the federal Age Discrimination in Employment Act,
the Americans with Disabilities Act, the Family and Medical 

 4
 

Leave
Act, the Washington Law Against Discrimination, or any other legal limitation
on the employment relationship.

5.9   Dispute
regarding existence of Good Reason for Termination

In the event the Company
disputes whether Good Reason existed for the Executive to terminate his
employment for Good Reason, the Company shall pay salary continuation as
provided in Section 5.5 until the earliest of (i) settlement by the
parties, (ii) determination by arbitration in accordance with Section 14
hereof that Good Reason did not exist, and (iii) completion of the
payments required by Section 5.5 and Section 5.1(c) hereof. If,
pursuant to Section 14 hereof, an arbitrator determines that Good Reason
did not exist, the arbitrator shall also decide whether the Executive had a
reasonable, good-faith basis for claiming that there was Good Reason to
terminate. If the arbitrator determines that there was not such a basis, the
Executive shall be obligated to repay promptly to the Company the salary
continuation payments; if the arbitrator determines that there was such a
basis, the Executive shall not be obligated to repay the salary continuation.

6.                 Representations,
Warranties and Other Conditions

In order to induce the
Company to enter into this Agreement, the Executive represents and warrants to
the Company as follows:

6.1   Health

The Executive is in good
health and knows of no physical or mental disability that, with any
accommodation that may be required by law and that places no undue burden on
the Company, would prevent him from fulfilling his obligations hereunder. The
Executive agrees, if the Company requests, to submit to reasonable periodic
medical examinations by a physician or physicians designated, paid for and
arranged by the Company. The Executive agrees that the examination’s medical
report shall be provided to the Company.

6.2   No
Violation of Other Agreements

The Executive represents
that neither the execution nor the performance of this Agreement by the
Executive will violate or conflict in any way with any other agreement by which
the Executive may be bound.

7.                 Nondisclosure;
Return of Materials

7.1   Nondisclosure

Except as required by his
employment with the Company, the Executive will not, at any time during the
term of employment by the Company, or at any time thereafter, directly,
indirectly or otherwise, use, communicate, disclose, disseminate, lecture upon
or publish articles relating to any confidential, proprietary or trade secret
information without the prior written consent of the Company. The Executive
understands that the Company will be relying on this covenant in continuing the
Executive’s employment, paying his compensation, granting him any promotions or
raises, or entrusting him with any information that helps the Company compete
with others.

7.2   Return
of Materials

All documents, records,
notebooks, notes, memoranda, drawings or other documents made or compiled by
the Executive at any time while employed by the Company, or in his possession,
including any and all copies thereof, shall be the property of the Company and
shall be held by the Executive in trust and 

 5
 

solely
for the benefit of the Company, and shall be delivered to the Company by the
Executive upon termination of employment or at any other time upon request by
the Company.

8.                 Notice
and Cure of Breach

Whenever a breach of this
Agreement by either party is relied upon as justification for any action taken
by the other party pursuant to any provision of this Agreement, other than
clause (a), (b), (c) or (d) of Section 5.6 hereof, before such
action is taken, the party asserting the breach of this Agreement shall give
the other party at least twenty (20) days’ prior written notice of the
existence and the nature of such breach before taking further action hereunder
and shall give the party purportedly in breach of this Agreement the
opportunity to correct such breach during the twenty (20) day period.

9.                 Form of
Notice

Every
notice required by the terms of this Agreement shall be given in writing by
serving the same upon the party to whom it was addressed personally or by
registered or certified mail, return receipt requested, at the address set
forth below or at such other address as may hereafter be designated by notice
given in compliance with the terms hereof:

	
  If to the Executive:

  	
  Alan B. Glassberg, M.D.

  
	
   

  	
  126 Poplar Drive

  
	
   

  	
  Kentfield, California 94904

  
	
  If to the
  Company:

  	
  Poniard
  Pharmaceuticals, Inc.

  
	
   

  	
  300 Elliott Avenue West, Suite 500

  
	
   

  	
  Seattle, Washington 98119

  
	
   

  	
  Attn: Chief Executive Officer

  
	
  With a copy to:

  	
  Perkins Coie LLP

  
	
   

  	
  1201 Third Avenue, 40th Floor

  
	
   

  	
  Seattle, Washington 98101-3099

  
	
   

  	
  Attn: James R. Lisbakken

  

 

Except as set forth in Section 4.4
hereof, if notice is mailed, such notice shall be effective upon mailing.

10.          Assignment

This Agreement is personal to the Executive and shall
not be assignable by the Executive.

The Company shall assign
to and require any successor (whether direct or indirect, by purchase, merger,
consolidation or otherwise) to all or substantially all the business and/or
assets of the Company to assume expressly and agree to perform this Agreement
in the same manner and to the same extent that the Company would be required to
perform it if no such succession had taken place. As used in this Agreement,
the “Company” shall mean Poniard Pharmaceuticals, Inc.
and any affiliated company or successor to its business and/or assets as
aforesaid that assumes and agrees to perform this Agreement by contract,
operation of law or otherwise; and as long as such successor assumes and agrees
to perform this Agreement, the termination of the Executive’s employment by one
such entity and the immediate hiring and continuation of the Executive’s
employment by the succeeding entity shall not be deemed to constitute a
termination or trigger any severance obligation under this Agreement. All the
terms and provisions of this Agreement shall be binding upon and inure to the
benefit of and be enforceable by the parties hereto and their respective
successors and permitted assigns.

 6
 

11.          Waivers

No delay or failure by any
party hereto in exercising, protecting or enforcing any of its rights, titles,
interests or remedies hereunder, and no course of dealing or performance with
respect thereto, shall constitute a waiver thereof. The express waiver by a
party hereto of any right, title, interest or remedy in a particular instance
or circumstance shall not constitute a waiver thereof in any other instance or
circumstance. All rights and remedies shall be cumulative and not exclusive of
any other rights or remedies.

12.          Amendments
In Writing

No amendment,
modification, waiver, termination or discharge of any provision of this
Agreement, or consent to any departure therefrom by either party hereto, shall
in any event be effective unless the same shall be in writing, specifically
identifying this Agreement and the provision intended to be amended, modified,
waived, terminated or discharged and signed by the Company and the Executive,
and each such amendment, modification, waiver, termination or discharge shall
be effective only in the specific instance and for the specific purpose for
which given. No provision of this Agreement shall be varied, contradicted or
explained by any oral agreement, course of dealing or performance or any other
matter not set forth in an agreement in writing and signed by the Company and
the Executive.

13.          Applicable
Law

This Agreement shall in
all respects, including all matters of construction, validity and performance,
be governed by, and construed and enforced in accordance with, the laws of the
State of Washington, without regard to any rules governing conflicts of
laws.

14.          Arbitration;
Attorneys’ Fees

Except in connection with
enforcing Section 7 hereof, for which legal and equitable remedies may be
sought in a court of law, any dispute arising under this Agreement shall be
subject to arbitration. The arbitration proceeding shall be conducted in
accordance with the Commercial Arbitration Rules of the American
Arbitration Association (the “AAA Rules”)
then in effect, conducted by one (1) arbitrator either mutually agreed
upon or selected in accordance with the AAA Rules. The arbitration shall be
conducted in King County, Washington, under the jurisdiction of the Seattle
office of the American Arbitration Association. The arbitrator shall have authority
only to interpret and apply the provisions of this Agreement, and shall have no
authority to add to, subtract from or otherwise modify the terms of this
Agreement. Any demand for arbitration must be made within sixty (60) days of
the event(s) giving rise to the claim that this Agreement has been
breached. The arbitrator’s decision shall be final and binding, and each party
agrees to be bound by the arbitrator’s award, subject only to an appeal
therefrom in accordance with the laws of the State of Washington. Either party
may obtain judgment upon the arbitrator’s award in the Superior Court of King
County, Washington.

If it becomes necessary to
pursue or defend any legal proceeding, whether in arbitration or court, in
order to resolve a dispute arising under this Agreement, the prevailing party
in any such proceeding shall be entitled to recover its reasonable costs and
attorneys’ fees.

15.          Severability

If any provision of this
Agreement shall be held invalid, illegal or unenforceable in any jurisdiction,
for any reason, including, without limitation, the duration of such provision,
its geographical scope or the extent of the activities prohibited or required
by it, then, to the full extent permitted by law, (a) all other provisions
hereof shall remain in full force and effect in such jurisdiction and shall be
liberally construed in order to carry out the intent of the parties hereto as
nearly as may be possible, (b) such invalidity, illegality or
unenforceability shall not affect the validity, legality or enforceability of
any other provision hereof, and 

 7
 

(c) any
court or arbitrator having jurisdiction thereover shall have the power to
reform such provision to the extent necessary for such provision to be
enforceable under applicable law.

16.          Coordination
With Change of Control Agreement

The
Company and the Executive are contemporaneously with this Agreement entering
into a Change of Control Agreement (the “Change of Control
Agreement”), which agreement provides for certain forms of
severance and benefit payments in the event of termination of Executive’s
employment under certain defined circumstances. This Agreement is in addition
to the Change of Control Agreement, providing certain assurances to the
Executive in circumstances that the Change of Control Agreement does not cover,
and in no way supersedes or nullifies the Change of Control Agreement. Nevertheless,
it is possible that a termination of employment by the Company or by the
Executive may fall within the scope of both agreements. In such event, payments
made to the Executive under Section 5.1 hereof shall be coordinated with
payments made to the Executive under Section 8.1 of the Change of Control
Agreement as follows:

(a)   Accrued Obligations under this Agreement need not be paid if paid
under the Change of Control Agreement;

(b)   COBRA Continuation under this Agreement need not be provided if
provided under the Change of Control Agreement; and

(c)   the severance payment required under Section 5.1(c) hereof
need not be paid during the first six (6) months of the Payment
Period if a severance payment is made under Section 8.1(d) of the
Change of Control Agreement; provided that the remaining one-third balance of
the severance payment required under Section 5.1(c) hereof shall be
paid during the Payment Period as provided herein.

17.          Excess
Parachute Payments

Unless provided by Section 8.8
of the Change of Control Agreement, if any portion of the payments or benefits
under this Agreement or any other agreement or benefit plan of the Company
(including stock options) would be characterized as an “excess parachute
payment” to the Executive under Section 280G of the Internal Revenue Code
of 1986, as amended (the “Code”), the
Executive shall be paid any excise tax that the Executive owes under Section 4999
of the Code as a result of such characterization, such excise tax to be paid to
the Executive at least ten (10) days prior to the date that he is
obligated to make the excise tax payment. The determination of whether and to
what extent any payments or benefits would be “excess parachute payments” and
the date by which any excise tax shall be due, shall be determined in writing
by recognized tax counsel selected by the Company and reasonably acceptable to
the Executive.

18.          Entire
Agreement

Except as described in Section 16
hereof, this Agreement constitutes the entire agreement between the Company and
the Executive with respect to the subject matter hereof, and all prior or
contemporaneous oral or written communications, understandings or agreements
between the Company and the Executive with respect to such subject matter, are
hereby superseded and nullified in their entireties, except that the
Proprietary Information and Invention Agreement between the Executive and the Company
shall continue in full force and effect to the extent not superseded by Section 10
hereof.

19.          Withholding

The Company may withhold
from any amounts payable under this Agreement such federal, state or local
taxes as shall be required to be withheld pursuant to any applicable law or
regulation.

20.          Counterparts

This Agreement may be
executed in counterparts, each of which counterpart shall be deemed an
original, but all of which together shall constitute one and the same
instrument.

 8
 

IN
WITNESS WHEREOF, the parties have executed and entered into this Agreement
effective on the date first set forth above.

	
  

  	
  PONIARD
  PHARMACEUTICALS, INC.

  
	
   

  	
  By:

  	
  /s/ ANNA L. WIGHT

  	
   

  
	
   

  	
   

  	
  Name:

  	
  Anna L. Wight

  	
   

  
	
   

  	
   

  	
  Its:

  	
  VP Legal

  	
   

  
	
   

  	
  EXECUTIVE

  
	
   

  	
  By:

  	
  /s/ ALAN B. GLASSBERG

  	
   

  
	
   

  	
   

  	
  Name: Alan B. Glassberg, M.D.

  	
   

  

 

 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]